title: Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?
abstract: Molecular prostate cancer subtypes have been proposed on the basis of mutually exclusive SPINK1 and ERG overexpression, with conflicting reports on their prognostic ability. Flavin and colleagues report that SPINK1 is neither prognostic nor absolutely mutually exclusive with ERG, raising important questions about prostate cancer molecular subtyping and prognostic biomarker evaluation.
authors.affiliation: Department of Pathology, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan. Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
authors.forename: Steven C
authors.initials: SC
authors.lastname: Smith
authors.affiliation: Department of Pathology, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan. Department of Urology, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan. Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan. tomlinss@umich.edu.
authors.forename: Scott A
authors.initials: SA
authors.lastname: Tomlins
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D002352:Carrier Proteins / Q000032:analysis / Q000096:biosynthesis; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D015534:Trans-Activators / Q000032:analysis / Q000096:biosynthesis; D000071230:Transcriptional Regulator ERG; D014359:Trypsin Inhibitor, Kazal Pancreatic
chemical_list: D014408:Biomarkers, Tumor; D002352:Carrier Proteins; C072312:ERG protein, human; C486642:SPINK1 protein, human; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; D014359:Trypsin Inhibitor, Kazal Pancreatic